ea0035oc12.2 | Pituitary Basic | ECE2014
Ibanez-Costa Alejandro
, Gahete Manuel David
, Jimenez-Reina Luis
, Rivero-Cortes Esther
, Lopez-Sanchez Laura Maria
, Galvez Maria Angeles
, de la Riva Andres
, Benito-Lopez Pedro
, Venegas-Moreno Eva
, Angel Japon Miguel
, Moreno Alberto
, Garcia-Arnes Juan Antonio
, Maraver-Selfa Silvia
, Angel Arraez Miguel
, Leal-Cerro Alfonso
, Schmid Herbert A.
, Tinahones Francisco J.
, Soto-Moreno Alfonso
, Castano Justo P.
, Luque Raul M.
Somatostatin analogs (SSA) are a first-line treatment for pituitary adenomas (PA). Indeed, multi-receptor targeting SSA such as octreotide and pasireotide are being successfully used to control hormone secretion and/or tumor growth. Unfortunately, many PA escape from SSA-therapy, which could be related to somatostatin receptor (sst) presence, abundance, availability and/or signaling. In order to better define the molecular/cellular features associated to octreotide and pasireo...